Lucy Stewart, Andrea Roberts, Richard Warren and Christopher Griffiths
This review will focus on the use of biological therapies (therapeutic agents produced by the application of recombinant biotechnology) in psoriasis but will also highlight the growing list of dermatological diseases where these novel drugs may have a role. Biological therapies are proteins with a pharmacological activity, which have been extracted from animal tissue or produced via recombinant DNA technologies. Advances over the past 25 years have meant that these manufactured proteins can be used in the management of a variety of inflammatory conditions, such as Crohn’s disease and rheumatoid arthritis, as well as in dermatological conditions such as psoriasis.
Dermatology in practice 2006; 14(2): 18–21
To continue reading this article, please
sign in or
register.